Legemidler i behandlingen av kreftsykdommer

Adams VR, Leggas M (2007): Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther. 29, 1338-1353.

Andersson BS, Madden T, Tran HT, Hu WW, Blume KG, Chow DS, Champlin RE, Vaughan WP (2000): Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant. 6, 548-554.

Bareschino MA, Schettino C, Troiani T, Martinelli E, Morgillo F, Ciardiello F (2007): Erlotinib in cancer treatment. Ann Oncol. 18, vi35-vi41.

Bennouna J, Delord JP, Campone M, Nguyen L (2008): Vinflunine: a new microtubule inhibitor agent. Clin Cancer Res. 14, 1625-1632.

Buesa JM, Urrechaga E (1991): Clinical pharmacokinetics of high-dose DTIC. Cancer Chemother Pharmacol. 28, 475-479.

Buie LW, Epstein SS, Lindley CM (2007): Nelarabine: a novel purine antimetabolite antineoplastic agent. Clin Ther. 29, 1887-1899.

Carter NJ, Keam SJ (2007): Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 67, 2257-2276.

Chang TK, Yu L, Goldstein JA, Waxman DJ (1997): Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics 7, 211-221.

Chattopadhyay S, Moran RG, Goldman ID (2007): Pemetrexed: biomedical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther. 6, 404-417.

Chen N, Lau H, Kong L, Kumar G, Zeldis JB, Knight R, Laskin OL (2007): Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects with hemodialysis. J Clin Pharmacol. 47, 1466-1475.

Cheson BD, Dutcher BS (2005): Managing malignancy-associated hyperuricemia with rasburicase. J Support Oncol. 3, 117-124

Choueiri TK, Alemany CA, Abou-Jawde RM, Budd GT (2004): Role of aromatase inhibitors in the treatment of breast cancer. Clin Ther. 26, 1199-1214.

Curran MP, Croom KF, Goa KL (2004): Spotlight on imatinib mesylate in chronic myeloid leukemia. BioDrugs 18, 207-210.

Dahl O, Lehne G, Baksaas I, Kvaløy S, Christoffersen T (red.): Medikamentell kreftbehandling. Cytostatikaboken 7. utg. 2009. Farmakologisk Institutt, Det medisinske fakultet, Universitetet i Oslo.

Deininger MW (2008): Nilotinib. Clin Cancer Res. 14, 4027-4031.

Desoize B, Madoulet C (2002): Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol. 42, 317-325.

Falco P, Cavallo F, Larocca A, Liberati AM, Musto P, Boccadoro M, Palumbo A (2008): Lenalidomide and its role in the management of multiple myeloma. Expert Rev Anticancer Ther. 8, 865-874.

Fleming RA (1997): An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy 17,146S-154S.

Gebbia V, Puozzo C (2005): Oral versus intravenous vinorelbine: clinical safety profile. Expert Opin Drug Saf. 4, 915-928.

Gillis JC, Goa KL (1995): Tretinoin. A review of its pharmacodynamic and pharmacokinetic properties and use in the management of acute promyelocytic leukemia. Drugs 50, 897-923.

Gwilt PR,Tracewell WG (1998): Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin Pharmacokinet. 34, 347-358.

Hartmann JT, Lipp HP (2006): Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile. Drug Saf. 29, 209-230.

Holte H, Smeland S, Blystad AK, Kvaløy S, Hammerstrøm J, Tjønnfjord GE (2002): Intensiv kjemoterapi ved Burkitts lymfom og aggressivt non-Hodgkins lymfom.Tidsskr Nor Legeforen. 122, 364-369.

Houle JM, Clervoix N, Bain S, Spénard J (2006): Lack of effect of sex and disease state on the pharmacokinetics of porfimer sodium. Clin Pharmacokinet- 45, 923-930.

Issa JPJ, Kantarjian HM, Kirkpatrick P (2005): Azacitidine. Nature Rev Drug Discovery 4, 275-276.

James CA, Mant TG, Rogers HJ (1987): Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. Br J Clin Pharmacol- 23, 561-568.

Jones RJ (2008): Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. Expert Rev Cardiovasc Ther- 6, 1311-1317.

Jurlina JL, Varcoe AR, Paxton JW (1985): Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia. Cancer Chemother Pharmacol- 14, 21-25.

Kitamura T (2001): Necessity of re-evaluation of estramustine phosphate sodium (EMP) as a treatment option for first-line monotherapy in advanced prostate cancer. Int J Urol. 8, 33-36.

Kumar S, Rajkumar SV (2006): Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer 42, 1612-1622.

Langer SW (2007): Dexrazoxane for anthracycline extravasation. Expert Rev Anticancer Ther. 7, 1081-1088.

Lobert S, Puozzo C (2008): Pharmacokinetics, metabolites, and preclinical safety of vinflunine. Semin Oncol 35 (Suppl 3), S28-S33.

Narta UK, Kanwar SS, Azmi W (2007): Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Crit Rev Oncol Hematol. 61, 208-221.

Petrides PE, Gisslinger H, Steurer M, Linkesch W, Krumpl G, Schüller A, Widmann R (2009): Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation. Clin Ther. 31, 386-398.

Reck M (2009): Gefitinib in the treatment of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther. 9, 401-412.

Reigner B, Blesch K, Weidekamm E (2001): Clinical pharmaokinetics of capecitabine. Clin Pharmacokinet. 40, 85-104.

Ricciardi S, Tomao A, de Marinis F (2009): Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 10, 28-35.

Sanford M, Plosker GL (2008): Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer. Drugs 68, 1319-1340.

Sanford M, Lyseng-Williamson KA (2008): Nelarabine. Drugs 68, 439-447.

Schteingart DE (2007): Adjuvant mitotane therapy of adrenal cancer - use and controversy. N Engl J Med. 356, 2415-2418.

Schwartz R, Davidson T (2004): Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology 18, 14-21.

Scripture CD, Sparreboom A, Figg WD (2005): Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol. 6, 780-789.

Siddiqui MAA, Scott LJ (2005): Azacitidine in myelodysplastic syndromes. Drugs 65, 1781-1789.

Spratlin J, Sawyer MB (2007): Pharmacogenetics of paclitaxel metabolim. Crit Rev Oncol Hematol. 61, 222-229.

Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, Schwartz B (2007): Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patinets with advanced refractory solid tumors. Oncologist 12, 426-437.

Triesscheijn M, Ruevekamp M, Out R, Van Berkel TJ, Schellens J, Baas P, Stewart FA (2007): The pharmacokinetic behavior of the photosensitizer meso-tetra-heydroxyphenylchlorin in mice and men. Cancer Chemother Pharmacol. 60, 113-122.

van Schaik RH (2008): CYP450 pharmacogenetics for peronalizing cancer therapy. Drug Resist Updat. 11, 77-98.

Verweij J, Pinedo HM (1990): Mitomycin C: mechanism of action, usefulness and limitations. Anticancer Drugs 1, 5-13.

Wilson J, Connock M, Song F, Yao G, Fry-Smith A, Raftery J, Peake D (2005): Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. Health Technol Assess. 9, 1-142.

Yun-San Yip A, Yen-Yen Ong E, Chow LW (2008): Vinflunine: clinical perspectives of an emerging anticancer agent. Expert Opin Investig Drugs 17, 583-591.

Preparatomtaler: www.legemiddelverket.no , www.ema.europa.eu , www.medicines.org.uk , www.medsafe.govt.nz , www.axcan.com